Sakigake designation for EZH1/2 dual inhibitor valemetostat

Daiichi Sankyo (TYO: 4568) says that valemetostat (DS-3201), an investigational and potential first-in-class EZH1/2 dual inhibitor, has received Sakigake designation for the treatment of adult patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) by the Japan Ministry of Health, Labor and Welfare (MHLW).

“There is a need for new and novel treatment approaches for patients with peripheral T-cell lymphoma, a group of heterogenous diseases for which relapse rates tend to be high and options beyond systemic chemotherapy are limited,” said Kaszushi Araki, valemetostat global team leader, Oncology Clinical Development Department, Oncology Function, Daiichi Sankyo. “We look forward to working closely with the Japan Ministry of Health, Labor and Welfare to optimize development of valemetostat and to potentially offer a new, first-in-class targeted therapy option for patients with various subtypes of relapsed/refractory PTCL, including those that are more common in Japan.”

Means six-month review period